CTRI/2012/01/002315尚未招募3 期
Comparative Evaluation of Efficacy and Safety of Clonazepam-CR and Conventional Clonazepam in Patients with Panic Disorder.
Ipca Laboratories Ltd Mumbai0 个研究点目标入组 232 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 232
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •General Health
- •-Satisfactory medical assessment with no clinically significant or relevant abnormalities except for study related disease condition
- •Conditions under study
- •-Patients meeting the DSM-IV-TR criteria for panic disorder with or without agoraphobia, as diagnosed by structured clinical interview for DSM-IV-TR
- •-Patients who have experienced at least 4 panic attacks during 4 weeks preceding screening visit
- •-Patients having at-least 1 panic attack during 1-week placebo period
- •-Patients with Clinical global impressions of severity (CGI-S) score for panic disorder of at least 4.
- •-Patients with co-morbid major depressive disorder may be included provided that the onset of panic disorder was earlier than the onset of the depressive disorder.
- •-Patient and LAR (if required) must understand and be able, willing and likely to fully comply with study procedures and restrictions.
- •-Patients who are willing to adhere to visit schedule and keep record of panic attack details in diaries during the entire study period
- •Informed Consent
- •-Patient and LAR (if required) must have given written, personally signed and dated, informed consent to participate in the study, in accordance with the current applicable regulations, International Conference on Harmonization (ICH), Good Clinical Practice (GCP) Guidelines, before completing any study related procedures. (In case of illiterate patients, patientâ??s thumb impression and signature of LAR/impartial witness is necessary on informed consent).
排除标准
- •Conditions under study
- •-Any current physical or mental condition that would limit ability to complete the study, increase the patientâ??s risk, or obscure efficacy measures
- •-Primary diagnosis of major depression, dysthymia, social phobia, or generalized anxiety disorder
- •-Patients with or history of organic mental disorder, schizophrenia, bipolar disorder, or obsessive compulsive disorder
- •-Patients with score of 18 on the Hamilton Rating Scale for Depression (HAM-D)
- •-Patients who are currently at high risk for homicide or suicide
- •-Patients with current or history of post-traumatic stress disorder including epilepsy, meningitis, parkinsonism or risk of respiratory depression
- •Concurrent disease
- •-Patients with abnormal ECG, recent or history of cardiovascular accident
- •-Patients who are known case of uncontrolled narrow-angle glaucoma
- •-Patients with systolic BP 160 mm Hg and/or diastolic BP 110 mm Hg
- •-Patients with abnormal renal function
- •-Patients with abnormal liver function
- •-Patients with uncontrolled diabetic mellitus (random blood sugar 200mg/dL)
- •-Concomitant medications
- •-Patients who have recently begun cognitive-behavioral psychotherapy to treat panic disorder, generalized anxiety disorder, or major depression
- •-Patients having any concomitant medication, which may interact with action of study drugs (antidepressants, lithium, and CNS stimulants like caffeine and cocaine)
- •Allergy / Intolerance
- •-Patients with known history of hypersensitivity or allergy to any benzodiazepines or any other ingredient of the study medication
- •Substance abuse
- •-Patients with history of drug dependence or excessive alcohol intake on a habitual basis of more than two units of alcoholic beverages per day (1 unit equivalent to half pint of beer or 1 glass of wine or measure of spirit) or have difficulty in abstaining for the duration of the study
- •-Patients with habitual smoking
- •Other clinical trials / experimental medications
- •-Patients who have used another investigational agent / device or participated in a clinical trial within the last 30 days prior to enrollment
- •-Pregnant or lactating women
- •-Women of childbearing potential not practicing contraception
研究者
相似试验
尚未招募
4 期
Microneedling with topical autologous Platelet rich plasma versus intralesional Triamcinolone acetonide in Alopecia AreataCTRI/2021/03/031963Dr Surabhi Dayal
尚未招募
Unknown
CAL(Cell assisted lipo-transfer) in treating recurrent complex anal fistulaKCT0008334Hangun Hospital Bumcheon Campus20
进行中（未招募）
1 期
An evaluation of the safety and effectiveness of combination therapy using the thiazolidinedione pioglitazone alongside insulin in type 2 diabetes mellitus.Type 2 Diabetes MellitusEUCTR2006-001982-41-GBBradford Teaching Hospitals NHS Foundation Trust40
尚未招募
3 期
Clinical trial to study the effect of a combination of propolis, vitamin C and vitamin E on the wound healing after wisdom tooth surgery.CTRI/2020/06/026019DR KARISHMA MOTWANI
已完成
2 期
A study investigating the efficacy and safety of CNS prophylaxis with R-CHOP and high-dose methotrexate in patients with de novo diffuse large B-cell lymphoma who have high risk for CNS relapse.Diffuse large B-cell lymphomaJPRN-UMIN000013540Department of Hematology and Oncology, Osaka University Graduate School of Medicine100